Neumirna Therapeutics is an RNA-focused biotechnology company developing RNA-based therapies and a drug discovery platform targeting previously intractable conditions. Its lead asset, NMT.001, is a potential disease-modifying Antisense Oligonucleotide (ASO) therapy for drug-resistant epilepsy. The company plans to use the funds to support clinical development of NMT.001. Neumirna also intends to expand its R&D capabilities and scale its pioneering drug discovery platform. It is developing programs for indications including drug-resistant epilepsy and Parkinson’s disease. The company is led by CEO Professor Janine Erler and was founded in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen and Lars Hellerung Christiansen in Copenhagen.

Total raised

$23M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2025